Getinge announces date of 2012 Q2 report and conference call

Getinge will issue it’s Q2 report for 2012 on Wednesday 11th of July 2012 at
08:30 CET, followed by a conference call at 10:00 CET, hosted by Johan
Malmquist, CEO, and Ulf Grunander, CFO.

To participate in the conference, please dial:
Swedish dial in number: +46 (0)8 5352 6408
UK dial in number: +44 (0)20 7784 1036
Participant passcode: 4961269

Agenda
09.45 Call in to the conference
10.00 Review of the Q2 report
10.20 Questions & answers
11.00 Close of the conference

A recorded version of the conference can be accessed for 5 working days on the
following number:
Sweden: +46 (0)8 5051 3897
UK: +44 (0)20 3427 0598
Code: 4961269

During the telephone conference a presentation will be held. To access the
presentation, please use this link:
http://www.livemeeting.com/cc/premconfeurope/join?id=4961269
&role=attend&pw=pw4712 (http://www.livemeeting.com/cc/premconfeurope/join?id=496
1 
269%20&role=attend&pw=pw4712)
Alternatively enter the VisionCast site and log into your meeting using the
Meeting ID and Password below:
VisionCast: http://www.euvisioncast.com
Your Name: (Enter your name)
Web Meeting ID: 4961269
Web Meeting Password: pw4712

For more information, please contact:
Sofie Melin
Investor Relations
Phone: +46 (0)10 335 5810
E-mail: sofie.melin@getinge.com
GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and life
sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions, interventional
cardiology and intensive care.
The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.